Preoperative chemotherapy for operable breast cancer

Area of Science:

• Oncology
• Clinical Trials
• Breast Cancer Research

Background:

• The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 study investigated the timing of chemotherapy administration for operable breast cancer.
• Understanding the impact of neoadjuvant (preoperative) versus adjuvant (postoperative) chemotherapy is crucial for optimizing treatment strategies.

Purpose of the Study:

• To compare the efficacy of preoperative versus postoperative chemotherapy in patients with operable breast cancer.
• To assess clinical and pathologic response rates, axillary nodal status, and breast conservation rates associated with preoperative chemotherapy.

Main Methods:

• The NSABP B-18 study involved patients with operable breast cancer receiving either preoperative or postoperative chemotherapy.
• Outcomes assessed included disease-free survival (DFS), overall survival, clinical and pathologic response, and breast conservation rates.

Main Results:

• Preoperative and postoperative chemotherapy yielded similar disease-free survival and overall survival outcomes.
• Preoperative chemotherapy demonstrated high clinical response rates but lower pathologic response rates in the breast.
• Significant axillary nodal downstaging and increased breast conservation rates were observed with preoperative chemotherapy.

Conclusions:

• Preoperative chemotherapy is a viable option for operable breast cancer, offering benefits in clinical response and breast conservation without compromising survival.
• The findings support ongoing evaluation of neoadjuvant chemotherapy in randomized trials to further elucidate optimal timing for adjuvant therapy.